Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice

Rheumatology International

Volumn 30, Issue 8, 2010, Pages 1041-1048

  Hirabayashi, Yasuhiko ^a,b   Ishii, Tomonori ^b   Harigae, Hideo ^b  

^a Hikarigaoka Spellman Hospital   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DAS28ESR; Interleukin 6; Rheumatoid arthritis; Tocilizumab

Indexed keywords

METHOTREXATE; PREDNISOLONE; STEROID; TACROLIMUS; TOCILIZUMAB;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL PRACTICE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 77954426599     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1095-0     Document Type: Article

References (15)

1. FM Brennan IB McInnes 2008 Evidence that cytokines play a role in rheumatoid arthritis J Clin Invest 118 3537 3545 10.1172/JCI36389 1:CAS:528:DC%2BD1cXhtlGltLrJ 18982160
2. A Alonso-Ruiz JI Pijoan E Ansuategui A Urkaregi M Calabozo A Quintana 2008 Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety BMC Musculoskelet Disord 9 1 27 10.1186/1471-2474-9-52 (Pubitemid 351678129)
3. D van der Heijde L Klareskog R Landewé GA Bruyn A Cantagrel P Durez G Herrero-Beaumont Y Molad C Codreanu G Valentini R Zahora R Pedersen D MacPeek J Wajdula S Fatenejad 2007 Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis Arthritis Rheum 56 3928 3939 10.1002/art.23141 18050208 (Pubitemid 350262318)
4. K Sato M Tsuchiya J Saldanha Y Koishihara Y Ohsugi T Kishimoto MM Bendig 1993 Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth Cancer Res 53 851 856 1:CAS:528:DyaK3sXhs1Ojs7Y%3D 8428365
5. Y Ohsugi 2007 Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases Biol Pharm Bull 30 2001 2006 10.1248/bpb.30.2001 1:CAS:528:DC%2BD1cXisVCntQ%3D%3D 17978466 (Pubitemid 350097028)
6. N Nishimoto N Miyasaka K Yamamoto S Kawai T Takeuchi J Azuma T Kishimoto 2009 Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod Rheumatol 19 12 19 10.1007/s10165-008-0125- 1 1:CAS:528:DC%2BD1MXhsFKmsLk%3D 18979150
7. JS Smolen A Beaulieu A Rubbert-Roth C Ramos-Remus J Rovensky E Alecock T Woodworth R Alten 2008 Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial Lancet 371 987 997 10.1016/S0140-6736(08)60453-5 1:CAS:528:DC%2BD1cXjs1Sltbc%3D 18358926 (Pubitemid 351392039)
8. N Nishimoto J Hashimoto N Miyasaka K Yamamoto S Kawai T Takeuchi N Murata D van der Heijde T Kishimoto 2007 Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 66 1162 1167 10.1136/ard.2006.068064 1:CAS:528:DC%2BD2sXhtVKltL7O 17485422 (Pubitemid 47309731)
9. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J (2008) Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. doi: 10.1136/ard.2008.092866
10. SJ Janket JA Jones JH Meurman AE Baird TE Van Dyke 2008 Oral infection, hyperglycemia, and endothelial dysfunction Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 173 179 10.1016/j.tripleo.2007.06.027 17905606
11. P Ortiz NF Bissada L Palomo YW Han MS Al-Zahrani A Panneerselvam A Askari 2009 Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors J Periodontol 80 535 540 10.1902/jop.2009.080447 1:CAS:528:DC%2BD1MXltlSgsrw%3D 19335072
12. T Hannu R Inman K Granfors M Leirisalo-Repo 2006 Reactive arthritis or post-infectious arthritis? Best Pract Res Clin Rheumatol 20 419 433 10.1016/j.berh.2006.02.003 16777574 (Pubitemid 43843064)
13. T Yoneyama M Yoshida T Ohrui H Mukaiyama H Okamoto K Hoshiba S Ihara S Yanagisawa S Ariumi T Morita Y Mizuno T Ohsawa Y Akagawa K Hashimoto H Sasaki 2002 Oral care reduces pneumonia in older patients in nursing homes J Am Geriatr Soc 50 430 433 10.1046/j.1532-5415.2002.50106.x 11943036 (Pubitemid 34229396)
14. E Nemeth S Rivera V Gabayan C Keller S Taudorf BK Pedersen T Ganz 2004 IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J Clin Invest 113 1271 1276 1:CAS:528: DC%2BD2cXjvVOqsrY%3D 15124018
15. FM McQueen N Stewart J Crabbe E Robinson S Yeoman PL Tan L McLean 1998 Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset Ann Rheum Dis 57 350 356 10.1136/ard.57.6.350 1:STN:280:DyaK1cvksVWnug%3D%3D 9771209